Clinical Trials on Breast Cancer in France

Total 5415 results

Daiichi Sankyo France

Recruiting

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer

HER2-positive Breast Cancer

France
Centre Hospitalier Universitaire de Besancon

Completed

IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) (IMBASSA)

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
UNICANCER
Gilead Sciences

Recruiting

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE)

Metastatic Breast Cancer | Triple Negative Breast Cancer

France
Institut de cancérologie Strasbourg Europe
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Recruiting

Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer (TNBC-RT2023)

Triple-negative Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Recruiting

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

Early Small (cT1N0) Triple Negative Breast Cancer

France
Centre Oscar Lambret
Laboratoire PRISM - Michel SALZET

Recruiting

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC)

Advanced Breast Cancer

France
Institut Paoli-Calmettes

Recruiting

Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy (NEO-R)

Breast Cancer Female

France
Centre Antoine Lacassagne

Active, not recruiting

Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer (RPOS+)

Localized Breast Cancer

France
University Hospital, Montpellier

Completed

Radioguided Occult Lesion Localisation by Indocyanine Green (ROLL-1)

Breast Cancer Female

France
Assistance Publique - Hôpitaux de Paris

Completed

Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer (ESTROTEPREDIC)

Metastatic Breast Cancer

France
University Hospital, Strasbourg, France

Completed

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope

Infiltrative Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
Centre Henri Becquerel

Completed

Study of ESR1 Mutations in Metastatic Breast Cancer (FMER)

Metastatic Breast Cancer

France
Institut Claudius Regaud
Fondation Toulouse Cancer Santé

Not yet recruiting

Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer (DP METABREAST)

Metastatic Breast Cancer

France
Institut Paoli-Calmettes

Active, not recruiting

Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node

Invasive Breast Cancer

France
Hôpital Privé des Côtes d'Armor (HPCA)

Completed

Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger (ARTEMIS)

Breast Cancer Female

France
ARCAGY/ GINECO GROUP

Completed

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

Metastatic Breast Cancer

France
Quanta Medical
Lattice Medical

Recruiting

First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer (TIDE)

Breast Reconstruction | Breast Cancer Female | Breast Cancer Prevent

Georgia, France
Institut Claudius Regaud

Completed

Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC (MIMOSA)

Triple Negative Breast Cancer

France
Centre Francois Baclesse

Recruiting

Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment (TRIPLEX)

Triple Negative Breast Cancer | Organoid

France
ARCAGY/ GINECO GROUP

Terminated

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

First Line Metastatic Breast Cancer

France
Institut Curie

Recruiting

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer (MONDRIAN)

HER2-negative Metastatic Breast Cancer

France
Centre Georges Francois Leclerc

Recruiting

Neoadjuvant Database (NEOADJ)

Neoadjuvant Treatment in Breast Cancer

France
Centre Francois Baclesse

Active, not recruiting

Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor. (PEPSI)

Breast Cancer | Metastatic Breast Cancer

France
Institut Claudius Regaud

Active, not recruiting

Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy. (MARTA)

Breast Cancer Invasive

France
UNICANCER
Clovis Oncology, Inc.; Fondation ARC

Completed

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (RUBY)

Metastatic Breast Cancer

France
Centre Jean Perrin

Terminated

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

Metastatic Breast Cancer

France
Centre Georges Francois Leclerc
Sanofi; GlaxoSmithKline

Completed

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer (LapDoc)

Metastatic Breast Cancer

France
Centre Georges Francois Leclerc

Recruiting

Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (EMEG-ECDD)

Localized Breast Cancer

France
University Hospital, Grenoble

Recruiting

Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (Néo-APBI-01)

Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast Cancer

France
Institut Paoli-Calmettes
Novartis Pharmaceuticals

Recruiting

Trans-RosaLEE Study: a Biomarker-directed, Translational Study (TransRosaLEE)

Advanced or Metastatic Breast Cancer (BC)

France
Institut Bergonié
Institut du Cancer de Montpellier - Val d'Aurelle; UNICANCER

Active, not recruiting

Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

Cancer

France
University Hospital, Grenoble

Recruiting

ACTIVPROSEIN : Professional Activity After Breast Cancer

Breast Cancer Female | Return to Work

France
Centre Jean Perrin

Recruiting

Adapted Physical Activity for Breast Cancer HER2 Positive Patient (APACAN2)

HER2 Positive Breast Cancer

France
UNICANCER
Pfizer; NanoString Technologies, Inc.

Completed

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women (NeoPAL)

Neoadjuvant Operable Breast Cancer

France
Centre Jean Perrin

Completed

Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure (COSMIK)

Local Breast Cancer Patients

France
Institut Cancerologie de l'Ouest
Telix Pharmaceutical; SIRIC ILIAD

Recruiting

Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)

Triple Negative Breast Cancer

France
Centre Jean Perrin

Recruiting

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients (INSTIGO)

Triple Negative Breast Cancer

France
University of California, Irvine
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
Centre Antoine Lacassagne
Thuasne

Recruiting

Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy (ARIANE)

Non-metastatic Breast Cancer

France
Centre Antoine Lacassagne

Recruiting

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS)

HER2 Negative Breast Cancer Not Immediately Operated

France
Institut de cancérologie Strasbourg Europe

Recruiting

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer (SIGHER)

HER2-positive Breast Cancer

France
Centre Antoine Lacassagne

Recruiting

Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (RPOS+2)

Localized Breast Cancer

France
Poitiers University Hospital

Recruiting

Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer

Breast Cancer | Gynecologic Cancer | Circulating Tumor DNA | Digestive Cancer | Exosomes

France
Institut Curie
Hoffmann-La Roche

Recruiting

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE)

Triple Negative Breast Cancer

France
Institut Curie
ProLynx LLC

Recruiting

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (TOPOLOGY)

Cancer | Breast

France
Institut Cancerologie de l'Ouest

Active, not recruiting

Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec) (RM2prepec)

Breast Cancer Female

France
Centre Jean Perrin

Terminated

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes (META2)

Metastatic Breast Cancer

France
Institut Paoli-Calmettes

Recruiting

Institut Paoli Calmettes Breast Cancer Database

Breast Cancer Diagnosis

France

3

Subscribe